• Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month
Page
  1. 1
    1
  2. 2
    2
  3. 3
    3
  4. 4
    4
  5. 5
    5
  6. 6
    6
  7. 7
    7
  8. 8
    8
  9. 9
    9
  10. 10
    10
  11. 11
    11
  12. 12
    12

GSK case study

Extracts from this document...

Introduction

Case Study on: GlaxoSmithKline Case OBJECTIVE: "GSK" TO SUPPLY ANTIRETROVIRALS AND ANTI-MALARIALS AT SUSTAINABLE PREFERENTIAL PRICES FOR ELIGIBLE CUSTOMERS IN THE LEAST DEVELOPED COUNTRIES AND ALL SUB-SAHARAN AFRICAN COUNTRIES. Eligible customers include the public sector, not-for-profit NGOs, aid agencies, UN agencies and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. Additionally, because of the gravity of the situation in sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics are also eligible. MADE BY: JIGAR.R.RAJPURA X-01824544 Sustainable Preferential Pricing Arrangements GlaxoSmithKline has offered preferential pricing for our HIV/AIDS medicines since 1997. They placed a high priority on their prices being sustainable. This means setting prices at levels that meet their costs, thereby ensuring they can sustain supply of these high-quality products for as long as they are needed. The Promise In 'Facing the Challenge' it is promised to: � extend preferential pricing to more products, countries and customers; � supply antiretrovirals and anti-malarials at preferential prices to public sector customers and not-for-profit organisations in 63 countries - all the Least Developed Countries of the world and all of sub-Saharan Africa; � supply ARV therapy at preferential prices to employers in sub-Saharan Africa who provide HIV/AIDS care and treatment directly to their staff through their own workplace clinics; � make thier ARVs and anti-malarials available at preferential prices to international purchase funds; � set up pilot projects with non-governmental organisations (NGOs) ...read more.

Middle

GRAPH A: SUPPLY ARRANGEMENTS BY CUSTOMER TYPE GRAPH B: CUMULATIVE SHIPMENTS OF COMBIVIR TABLETS 100 80 60 40 Employers Public Hospitals NGOs Govt Non AAI AAI 8000000 7000000 6000000 5000000 4000000 3000000 Combivir tablets 20 0 Q4 2000 Q1 2001 Q2 2001 Q3 2001 Q4 2001 Q1 2002 Q2 2002 2000000 1000000 0 Q1 2001 Q2 2001 Q3 2001 Q4 2001 Q1 2002 Q2 2002 Research and Development Continued investment in research into diseases that affect the developing world is essential to long-term improvement in the health of people in these regions, not least because of challenges such as development of drug resistance to current treatments and poor patient adherence. For neglected communicable diseases, GlaxoSmithKline already has one of the most extensive portfolios of novel products and development projects in the industry. We are the only company currently involved in R&D for both the prevention and treatment of all three top priority diseases of the World Health Organization: malaria, tuberculosis and HIV/AIDS. And we currently have between 20 and 30 R&D projects and programmes of relevance to the developing world, of which ten are aimed at producing medicines primarily for developing countries.GSK frequently pursues a public/private partnership (PPP) model for R&D into diseases of the developing world. ...read more.

Conclusion

1987 - Burroughs Wellcome (a GSK legacy company) introduces the first antiretroviral (ARV), zidovudine (AZT). 1992 - GSK establishes Positive Action. 1994 - US Food and Drug Administration (FDA) approves GSK's Retrovir for the prevention of mother-to-child transmission of HIV. 1996 - Combination therapy involving a 'cocktail' of drugs promises longer AIDS-free survival. 1997 - FDA approves GSK's Combivir, the first product to combine two ARVs in a single tablet. GSK is the first company to sell an ARV therapy at highly discounted prices to sub-Saharan Africa. 2000 - FDA approves GSK's Trizivir, the first combination of three ARVs in a single tablet. 2001 - 47 million people are infected with HIV, 26 million of these live in Africa. GSK grants its first voluntary licence for the manufacture of generic versions of our ARVs in South Africa. 2007 - HIV infection is no longer a death sentence for people in the developed world, but the epidemic is increasing in Africa and Asia.GSK remains to work efficiently in the tackling of AIDS. REFRENCES: 1) http://www.gsk.com/responsibility/cr-review-2006/case-studies/aids.htm 2) In May 2002 we published 'Performance with Integrity - a Review of GlaxoSmithKline's Commitment to Society and the Environment'. This publication expands on the information on medicines for the developing world in the review which can be found at: www.gsk.com/ser/2001/ser01/index-still.html 3) http://jama.ama-assn.org/issues/v286n15/rfull/jsc10222.html 4) http://mosquito.who.int 5) http://www.malariavaccine.org/ 6) http://www.ehealthcube.co.uk/community/downloads/facing_the_challenge_one_year_on.pdf ?? ?? ?? ?? 1 | Page ...read more.

The above preview is unformatted text

This student written piece of work is one of many that can be found in our AS and A Level Healthcare section.

Found what you're looking for?

  • Start learning 29% faster today
  • 150,000+ documents available
  • Just £6.99 a month

Not the one? Search for your essay title...
  • Join over 1.2 million students every month
  • Accelerate your learning by 29%
  • Unlimited access from just £6.99 per month

See related essaysSee related essays

Related AS and A Level Healthcare essays

  1. Marked by a teacher

    Investigating Diseases. I will be looking at and comparing communicable and non communicable diseases. ...

    4 star(s)

    This can cause them to become unfit, they may not be as active as they were before. Intellectually- They will find it hard to think about other things i.e. their future, education, friends, family and etc... Emotionally- they will feel upset and low self esteem about themselves.

  2. Complementary Therapies

    Lack of self-esteem, feelings of deep anger talk to a professional therapist to help you understand yourself and your situation. Counselling is a way of talking and having someone with you that is not going to judge you or take sides.

  1. Communicable and Non-Communicable Disease: Tuberculosis and Cystic Fibrosis

    Cystic fibrosis is most common among Caucasians of Northern European descent, as it is in this group that the faulty CFTR allele is most prevalent.45 Incidence rates are significantly lower among the African and Oriental races46, with incidence rates of just 1/17000 in African Americans and 1/31000 in Asian Americans, compared to 1/3600 in Caucasian Americans.

  2. Research In Clinical Practise

    Overall, in comparison to Morrell et al, Simon et al seem less likely to attain good quality research. Abstract Cormack (2000) enquires as to whether the abstract identifies the research problem. Crookes and Davies (1989) believe that an abstract is a brief summary of the article and usually identifies what type of information is being presented.

  1. Unit 4-Human lifespan development

    While most facets of child development have internal factors (temperament, genetics, and characteristics) and external factors (environment and social influences), morality is largely developed through external factors. Children's environments exert influence on their moral development in many different ways. Adult and peer modeling, family and societal values, religious values and

  2. Child development - patterns of development. To increase my awareness and knowledge of ...

    of Marie General weight 15months 19 pounds 23.26 pounds 18months 21 pounds 24.58 pounds 21months 23 pounds 25.79 pounds 24months 25pounds 28.4 pounds 36months 27 pounds 26.57 pounds Pre-school Weight of Marie General weight 3 years 30 pounds 30.8 pounds 4 years 33 pounds 35.2 pounds 5 years 36 pounds

  • Over 160,000 pieces
    of student written work
  • Annotated by
    experienced teachers
  • Ideas and feedback to
    improve your own work